2023 World Conference on Lung Cancer (Posters)-P1.28. Korean Real-world Data on Unresectable Stage III Non-Small Cell Lung Cancer Patients Treated with Durvalumab after Chemoradiotherapy

P1.28. Korean Real-world Data on Unresectable Stage III Non-Small Cell Lung Cancer Patients Treated with Durvalumab after Chemoradiotherapy - PDF(Abstract)

Back to course

Pdf Summary

This study investigated the use of durvalumab consolidation (DC) after chemoradiotherapy (CRT) in patients with unresectable stage III non-small cell lung cancer (NSCLC). The study included 157 patients treated at five tertiary hospitals in Korea. The primary endpoint was real-world progression-free survival (rwPFS), and secondary endpoints included overall survival (OS), objective response rate (ORR), and adverse events. <br /><br />At a median follow-up of 19.1 months, the median rwPFS for DC was 25.9 months, with 1-, 2-, and 3-year rwPFS rates of 59.4%, 51.8%, and 43.5%, respectively. The median OS was not matured, and the ORR of DC was 51.0%. High PD-L1 expression (50%) and the development of radiation pneumonitis (RP) requiring steroid treatment were associated with longer and shorter rwPFS, respectively. RP, RP requiring steroid treatment, and immune-related adverse events (irAEs) occurred in 36.3%, 26.8%, and 33.8% of patients, respectively. <br /><br />The study found that a high derived monocyte-to-lymphocyte ratio (dMLR) at the initiation of DC was the most significant risk factor for the development of RP requiring steroid treatment and irAEs. <br /><br />The study concluded that DC after CRT demonstrated favorable survival benefits in patients with unresectable stage III NSCLC compared to the results of the PACIFIC trial. It also suggested that blood-based biomarkers could predict the development of higher-grade RP and irAEs before the initiation of DC.

Asset Subtitle

Hyung-Joo Oh

Meta Tag

Speaker Hyung-Joo Oh

Topic Local-Regional NSCLC

Keywords

durvalumab consolidation

chemoradiotherapy

unresectable stage III non-small cell lung cancer

real-world progression-free survival

overall survival

objective response rate

adverse events

PD-L1 expression

radiation pneumonitis

immune-related adverse events